Description

Specifications

• Form: White lyophilized powder
• Standard vial size: 1mg
• Purity: ≥99% (HPLC & Mass Spec verified)
• Class: 83-amino-acid analog of human IGF-1 with extended half-life (Long Arg3 modification)
• Storage: Store lyophilized powder at -20°C; refrigerate at 2–8°C once reconstituted, requires bacteriostatic water + carrier protein (e.g., BSA) for solution stability

Overview

IGF-1 LR3 is a modified analog of insulin-like growth factor 1, engineered with an extra 13 amino acids at the N-terminus and an arginine substitution at position 3, which together dramatically reduce its binding affinity for IGF-binding proteins and extend its research half-life relative to native IGF-1.

Mechanism & Research Findings

By escaping sequestration by IGF-binding proteins, IGF-1 LR3 maintains substantially higher bioavailability in circulation, allowing sustained activation of the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR signaling — the central pathway governing protein synthesis and cell growth. It is a foundational reference compound in satellite-cell activation and skeletal-muscle hypertrophy research, as well as broader studies of the growth hormone/IGF-1 axis.

Research Applications

• IGF-1R / PI3K-Akt-mTOR signaling research
• Satellite-cell activation and muscle-hypertrophy studies
• IGF-binding protein interaction pharmacokinetics

For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.